Table 3 Adjusted effects of RC14-GR1 and LGG-BB12 treatments and other covariates on UTI-free survival

From: Probiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in persons with spinal cord injury [ProSCIUTTU]: a randomised controlled trial

Covariates

Hazard ratio (95% CI)

P-value (Likelihood ratio test)

RC14-GR1

  

  Placebo

1

0.17

  Active

0.67 (0.39, 1.18)

 

LGG-BB12

  

  Placebo

1

0.37

  Active

1.29 (0.74, 2.25)

 

Participant location at recruitment

  

  Inpatient

1

0.57

  Outpatient

0.79 (0.34, 1.81)

 

Gender

  

  Female

1

0.78

  Male

1.10 (0.55, 2.20)

 

Bladder management

  

  Indwelling catheter

1

0.95

  Suprapubic catheter

0.67 (0.26, 1.76)

 

  Intermittent catheter

0.78 (0.31, 1.98)

 

  Reflex voiding (±condom)

0.34 (0.04, 3.01)

 

Completeness of injurya

  

  Complete

1

0.03

  Incomplete

0.52 (0.29, 0.94)

 

Time since injury

0.99 (0.97, 1.02)

0.48

UTI 6 months prior to trial

1.24 (1.10, 1.40)

0.002

  1. aAmerican Spinal Injuries Association (ASIA) Impairment Scale (AIS) for neurological classification of SCI definition [16]
Back to article page